Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Influence of mannan-binding lectin and MAp44 on outcome in comatose survivors of out-of-hospital cardiac arrest

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognostic value of automated pupillometry: an unselected cohort from a cardiac intensive care unit

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cognitive impairment and psychopathology in out-of-hospital cardiac arrest survivors in Denmark: The REVIVAL cohort study protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: The lectin complement pathway, initiated by mannan-binding-lectin (MBL) plays a role in tissue destruction following ischemia/reperfusion, and MBL deficiency has been associated with favorable outcome in stroke patients. MAp44 is produced in the heart and may theoretically function as an endogenous inhibitor of MBL-mediated activities. The aim of this study was to investigate the possible association between MBL deficiency, MAp44 levels and outcome in comatose survivors of out-of-hospital cardiac arrest (OHCA).

METHODS: In a single center post hoc analysis of the prospective multicenter randomized Target Temperature Management (TTM) trial, we measured MBL and MAp44 levels at baseline, 24, 48 and 72 h after OHCA in 169 consecutive patients randomly assigned to TTM at 33 °C or 36 °C for 24h. Primary outcome was 30 days mortality and secondary outcome was favorable neurological outcome assessed by Cerebral Performance Category (CPC1-2) and modified Rankin Scale (mRS0-3) 180 days after OHCA.

RESULTS: Patients with MBL deficiency (defined as plasma levels ≤100 ngml(-1) at baseline) (n=22) carried a 30-day mortality of 41% compared to 32% in MBL sufficient patient (n=147), p=0.55. Baseline MAp44 levels were not associated with mortality, p=0.25. There was no significant difference in neurological outcome between the two MBL groups assessed by CPC (p=0.69) and mRS (p=0.91). In multivariable models, baseline MBL (OR=1.0, p=0.70), (OR=1.5, p=0.30) and MAp44 levels (OR=1.0, p=0.99), (OR=1.6, p=0.21) were not associated with favorable neurological outcome assessed by CPC and mRS, respectively.

CONCLUSIONS: In comatose survivors after cardiac arrest, neither MBL deficiency nor levels of MBL and MAp44 were associated with mortality or neurological outcome.

Original languageEnglish
JournalResuscitation
Volume101
Pages (from-to)27-34
Number of pages8
ISSN0300-9572
DOIs
Publication statusPublished - Apr 2016

    Research areas

  • Coma, Female, Humans, Male, Mannose-Binding Lectin, Mannose-Binding Protein-Associated Serine Proteases, Middle Aged, Out-of-Hospital Cardiac Arrest, Prospective Studies, Single-Blind Method, Survival Rate, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

ID: 49682274